News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Fast-Tracks U.S. Patent for MS Drug and Secures Broad Platform IP Covering Autoimmune Neurology Pipeline
BioNxt announces fast-tracked U.S. patent filing for BNT23001 sublingual thin-film cladribine formulation targeting neurological autoimmune disorders. Broad international patent core claims accepted for platform-level protection -
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Solutions Announces Closing of Final Tranche of Oversubscribed Convertible Debenture Unit Private Placement
BioNxt Solutions Inc. closes final tranche of non-brokered private placement, raising $241,200 for convertible debentures and issuing Warrants. Funds intended for product development and IP filings -